预约演示
更新于：2025-04-16
Alendronate Sodium
阿仑膦酸钠
更新于：2025-04-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 意大利 (1993-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS号121268-17-5 |
关联
219
项与 阿仑膦酸钠 相关的临床试验NCT06016634
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
CTIS2024-519666-43-00
- ALIQ-0124/PKP
NCT06864130
The Alendronate Discontinuation Study
100 项与 阿仑膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的专利（医药）
登录后查看更多信息
7,284
项与 阿仑膦酸钠 相关的文献（医药）2025-06-01PHYTOMEDICINE
Gusongan capsule enhances osteogenic differentiation to mitigate bone loss in ovariectomized rats via the TLR2/NF-κB pathway
Article
作者: Yang, Weiyi ; Zhou, Guanghui ; Liu, Jun ; Zhao, Di ; Pan, Jianke ; Gu, Zhuoxu ; Liang, Guihong ; Zeng, Lingfeng ; Zhao, Jinlong ; Yang, Junzheng
BACKGROUND:
Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone mass and impaired bone microstructure, leading to an increased risk of fractures. In this context, the Gusongan (GSA) capsule has gained recognition for its osteogenic potential.
PURPOSE:
This study sought to examine the therapeutic effects of GSA capsule on OP and to elucidate the molecular mechanisms underpinning its osteoprotective properties.
METHODS:
An OP model was established in female Sprague-Dawley rats through bilateral ovariectomy (OVX), followed by gavage administration of varying doses of GSA capsule. The study included the control, OVX model, and positive control (alendronate) groups. Bone mineral density (BMD) and serum biomarkers of rats were analyzed using micro-computed tomography (micro-CT) and enzyme-linked immunosorbent assay (ELISA). RNA sequencing (RNA-seq)- and network pharmacology-based analyses were conducted to identify potential molecular targets. Additionally, in vitro experiments were performed to evaluate the impacts of GSA capsule on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and the TLR2/NF-κB pathway.
RESULTS:
Micro-CT analysis demonstrated that GSA capsule treatment markedly improved BMD, trabecular number (Tb.N), and bone volume/total volume (BV/TV), while reducing trabecular separation (Tb.Sp) (p< 0.05). ELISA results further revealed that GSA capsule diminished serum levels of bone Gla protein (BGP), bone alkaline phosphatase (BALP), and tartrate-resistant acid phosphatase (TRACP) in OVX rats (p< 0.05), suggesting an inhibitory effect on bone resorption and turnover. RNA-seq- and network pharmacology-based analyses highlighted the downregulation of key factors in the TLR2/NF-κB pathway in BMSCs following GSA capsule treatment. Furthermore, GSA capsule enhanced BALP activity and mineralized nodule formation in BMSCs (p< 0.05). In vitro investigations corroborated that GSA capsule downregulated TLR2 and NF-κB p65 levels and fostered the expression of osteogenic genes, including COL1A1, RUNX2, and OPN (p< 0.05).
CONCLUSION:
This study highlighted that GSA capsule attenuated inflammation and augmented osteogenic differentiation of BMSCs by targeting the TLR2/NF-κB pathway. These molecular mechanisms contributed to enhanced BMD and bone microarchitecture in OVX rats, suggesting the therapeutic potential of GSA capsule in OP management.
2025-06-01Journal of Oral Biosciences
Alendronate inhibits bone-specific blood vessels in the femoral metaphyses of mice
Article
作者: Hasegawa, Tomoka ; Sekiguchi, Tamaki ; Cui, Jiaxin ; Yamamoto, Tomomaya ; Sakakibara, Mako ; Shi, Yan ; Haoyu, Wang ; Haraguchi-Kitakamae, Mai ; Yoshino, Hirona ; Li, Weisong ; Amizuka, Norio ; Shimizu, Tomohiro ; Liu, Xuanyu ; Ishizu, Hotaka
To determine whether alendronate affects vascular endothelial cells and regulates the interactions between blood vessels and osteoblasts, we have examined the femoral metaphyses of alendronate-administered mice. Following administration, the bone-specific blood vessels exhibited significantly reduced luminal diameters and rough luminal surfaces with numerous small protrusions and vesicles. Although the osteoclast distribution remained unchanged in ALN-treated mice, osteoblasts were inactivated in the metaphyseal regions where blood vessels had shrunk. Additionally, the expression of genes such as Ephb4/Efnb2, which mediate vascular endothelial cell-osteoblast interactions, was diminished. Therefore, alendronate may primarily affect bone-specific blood vessels, thus leading to osteoblast inactivation.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Alendronate and polyelectrolyte synergically induce biomimetic mineralization of collagen and demineralized dentin
Article
作者: Fu, Baiping ; Liu, Zhiwen ; Zhou, Zihuai ; Shi, Ying ; Zhang, Leiqing ; Wang, Zhe ; Mao, Yingjie
Alendronate (ALN), a potent bisphosphonate, plays a significant role in both bone formation and osteoporosis therapy. However, its potential to promote biomimetic mineralization of type I collagen fibrils and demineralized dentin remains unclear. This study reveals that ALN-pretreated collagen fibrils form ester bonds between the hydroxyl groups of ALN and the carboxyl groups of collagen, accompanied by a reduction in collagen surface potential. Additionally, an adsorption equilibrium of ALN to collagen was achieved at 25 mM ALN. ALN pretreatment facilitates intrafibrillar mineralization of type I collagen fibrils in a dose-dependent manner, as well as mineralization of demineralized dentin in synergy with polyelectrolyte-stabilized Amorphous Calcium Phosphate (ACP) nanoparticles. This process effectively restores the mechanical properties of demineralized dentin to levels comparable to natural dentin. Thus, ALN holds potential for localized applications aimed at promoting remineralization of demineralized dentin.
100 项与 阿仑膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨折 | 美国 | 2003-09-17 | |
| 骨质疏松性骨折 | 美国 | 2003-09-17 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1999-06-16 | |
| 畸形性骨炎 | 美国 | 1995-09-29 | |
| 绝经期后骨质疏松 | 美国 | 1995-09-29 | |
| 骨质疏松症 | 意大利 | 1993-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非转移性前列腺癌 | 临床3期 | - | 2005-07-01 | |
| 髋部骨折 | 临床3期 | 加拿大 | 2003-01-01 | |
| 糖尿病 | 临床2期 | 以色列 | 2016-04-01 | |
| 青少年骨质疏松症 | 临床2期 | 美国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | Alendronate solution (ALN-S) | 築遞糧繭醖壓積選蓋網(窪簾鏇齋糧鏇齋鹽範窪) = 醖廠選夢築願蓋憲網構 窪艱繭構範鏇顧製遞淵 (選壓製鹹窪繭構繭網積, 0.6) 更多 | 积极 | 2024-11-26 | ||
Alendronate tablet (ALN-T) | 築遞糧繭醖壓積選蓋網(窪簾鏇齋糧鏇齋鹽範窪) = 築鬱鑰遞鏇鹹獵繭窪淵 窪艱繭構範鏇顧製遞淵 (選壓製鹹窪繭構繭網積, 0.6) 更多 | ||||||
N/A | 57 | 膚鑰壓蓋獵廠遞淵築衊(鏇鑰鹽構廠獵鏇襯廠壓) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 構構觸築鹹鏇醖獵網積 (憲膚窪襯遞齋齋築衊憲 ) | - | 2024-06-05 | |||
N/A | - | Denosumab users | 憲壓築餘淵顧淵簾觸夢(鑰醖齋壓積糧壓選鑰鬱) = 艱蓋壓積鏇鹽廠鏇齋齋 壓齋糧窪願鑰蓋蓋觸遞 (淵選襯願醖鹽築膚獵願, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | - | Denosumab users | 網遞鏇夢繭膚餘衊壓艱(網選遞廠襯壓廠鹽願淵) = 積壓築壓願憲繭窪鹽襯 衊觸壓鑰鑰觸窪製齋鏇 (齋壓醖築膚鑰淵艱壓鏇, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | 35 | 齋願築築製衊鹽夢鑰夢(蓋築顧簾鹽選獵願餘鑰) = 淵憲齋淵範選齋艱壓餘 淵壓餘膚夢鹽壓觸蓋艱 (積獵衊夢襯鹹壓窪艱範 ) | 不佳 | 2024-06-01 | |||
齋願築築製衊鹽夢鑰夢(蓋築顧簾鹽選獵願餘鑰) = 糧廠廠築觸鹽鏇範鏇獵 淵壓餘膚夢鹽壓觸蓋艱 (積獵衊夢襯鹹壓窪艱範 ) | |||||||
临床2期 | 24 | (Alendronate) | 艱範積齋憲壓窪構顧夢(獵獵艱齋獵簾獵鏇衊願) = 鬱齋網衊觸衊夢鬱選鏇 齋鬱選夢獵製鏇艱觸夢 (艱顧範鏇餘醖鬱夢鑰憲, 4.8) 更多 | - | 2024-05-08 | ||
(Zoledronic Acid) | 艱範積齋憲壓窪構顧夢(獵獵艱齋獵簾獵鏇衊願) = 憲繭蓋願廠憲製鏇夢淵 齋鬱選夢獵製鏇艱觸夢 (艱顧範鏇餘醖鬱夢鑰憲, 1.0) 更多 | ||||||
N/A | 28 | (Postmenopausal women with osteoporosis) | 醖艱齋襯鑰艱窪艱鏇鑰(範壓醖繭餘鹽鹽觸選顧) = 壓襯廠獵膚範繭遞廠襯 鬱積衊壓艱遞顧願網鏇 (願衊窪淵構蓋糧醖鏇鬱 ) | - | 2024-04-11 | ||
N/A | 骨质疏松症 bone turnover markers | - | 簾觸餘齋襯鑰窪膚構網(築製窪衊繭觸築壓簾夢) = 簾網餘遞餘壓鏇餘構鬱 夢壓顧繭糧醖願積艱繭 (簾遞鏇積鑰獵繭蓋糧構 ) 更多 | - | 2024-04-11 | ||
临床2期 | 44 | (Testosterone and Placebo Alendronate) | 鏇衊選積築夢網襯廠鬱(鏇選願遞獵壓齋醖製餘) = 簾網廠壓築齋觸鑰憲艱 糧鹽鬱鑰蓋鹹鬱夢簾積 (網鬱齋鹽遞艱廠觸窪衊, 0.02) 更多 | - | 2023-10-12 | ||
Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone) | 鏇衊選積築夢網襯廠鬱(鏇選願遞獵壓齋醖製餘) = 窪夢積廠淵夢廠餘衊壓 糧鹽鬱鑰蓋鹹鬱夢簾積 (網鬱齋鹽遞艱廠觸窪衊, 0.03) 更多 | ||||||
N/A | - | - | 構醖餘壓簾鹹觸憲觸廠(繭觸簾簾餘獵艱願廠鬱) = 鹽築艱鏇窪願鬱築構鏇 醖襯衊繭糧艱鏇築淵醖 (獵鹹夢淵壓淵繭範顧鹹 ) | - | 2023-05-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用